“Our fundamental belief is that what we currently understand as these conditions that are treatment-resistant or intractable, we will have ways to treat them such that people can not just get to their baseline, but actually ultimately flourish. And that’s really, I would say, a huge focus of ours,” says Greg Kubin, as he refers to conditions like depression and PTSD. He discusses the future of mental health solutions and the role PsyMed Ventures plays in driving this change.
In this episode, Alex Raymond is joined by Greg Kubin and Ma...
“Our fundamental belief is that what we currently understand as these conditions that are treatment-resistant or intractable, we will have ways to treat them such that people can not just get to their baseline, but actually ultimately flourish. And that’s really, I would say, a huge focus of ours,” says Greg Kubin, as he refers to conditions like depression and PTSD. He discusses the future of mental health solutions and the role PsyMed Ventures plays in driving this change.
In this episode, Alex Raymond is joined by Greg Kubin and Matias Serebrinsky, partners at PsyMed Ventures, to talk about the intersection of psychedelics and venture capital. What does it take to invest in breakthrough therapies that could transform mental health care? Greg and Matias walk us through their mission to fund startups that tackle mental illness, from psychedelic medicine to neurotechnology, and explain why they believe healing, ethics, and profitability can align.
They also talk about the shifting landscape for psychedelics, especially with potential FDA approval for MDMA on the horizon, and how this could be a game-changer. How do these investors spot the right opportunities in such a complex and evolving field? And why is founder resilience so important in ventures like these? Tune in for an insightful discussion on how VC is driving real change in mental health.
Quotes
- “For me, investing is a means to an end. It’s a vehicle through which we have a positive impact… How we think about it is that we don’t get to choose between great returns and great societal impact. Without great returns, there’s no chance to keep on doing this for many, many more decades. And without societal impact, it’s like, why are we even focusing on this? What’s the point?” (09:23 | Matias Serebrinsky)
- “Our fundamental belief is that what we currently understand as these conditions that are treatment-resistant or intractable, we will have ways to treat them such that people can not just get to their baseline, but actually ultimately flourish. And that’s really, I would say, a huge focus of ours.” (13:40 | Greg Kubin)
- “Psychedelics definitely helped, and it helped scientists and researchers understand better how our brain works and what are the receptors that elicit certain behavioral changes and feelings and emotions.” (18:38 | Matias Serebrinsky)
- “At the end of the day, I think if you're going to introduce a new technology or way of operating into the world, there’s just so much status quo that you need that larger-than-life individual.” (24:03 | Greg Kubin)
- “In order to be supportive in that capacity, I think you first need to really establish a relationship that's based in trust and transparency and vulnerability.” (30:40 | Greg Kubin)
Links
Connect with Greg Kubin and Matias Serebrinsky:
Website: https://psymed.ventures/
Connect with Alex Raymond:
LinkedIn: https://www.linkedin.com/in/afraymond/
Website: https://amplifyam.com/
HiveCast.fm is a proud sponsor of The Conscious Entrepreneur Podcast.
Podcast production and show notes provided by HiveCast.fm
View more
